We are live on
!
Find out more
IC
Ikarian Capital Portfolio holdings
AUM
$1.23B
1-Year Est. Return
600.17%
This Fund
S&P 500
This Quarter
Est. Return
+17.58%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$2.97B
AUM Growth
+$703M
(+31%)
Cap. Flow
+$803M
Cap. Flow
% of AUM
27.04%
Top 10 Holdings %
Top 10 Hldgs %
34.36%
Holding
350
New
119
Increased
64
Reduced
60
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
|
+$25.3M |
| 2 |
Eli Lilly
LLY
|
+$24.5M |
| 3 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$18.4M |
| 4 |
X4 Pharmaceuticals
XFOR
|
+$15.7M |
| 5 |
MacroGenics
MGNX
|
+$12.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$21.4M |
| 2 |
KALV
KalVista Pharmaceuticals
KALV
|
+$20.2M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$17.9M |
| 4 |
Celldex Therapeutics
CLDX
|
+$17.7M |
| 5 |
Prothena Corp
PRTA
|
+$14.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.28% |
| 2 | Consumer Staples | 0.05% |
| 3 | Financials | 0.03% |
| 4 | Industrials | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
CALL
Gossamer Bio
GOSS
$82.9M
| $2.77M | 0.09% |
300,000
-81,300
| -21% | -$820K |
|
177
INmune Bio
INMB
$46.5M
| $2.77M | 0.09% |
233,576
+16,008
| +7% | +$288K |
|
178
Madrigal Pharmaceuticals
MDGL
$10.8B
| $2.77M | 0.09% |
23,654
| – | – |
|
179
InflaRx
IFRX
$250M
| $2.73M | 0.09% |
699,750
+550,000
| +367% | +$2.82M |
|
180
Avalo Therapeutics
AVTX
$965M
| $2.71M | 0.09% |
312
+242
| +346% | +$2.29M |
|
181
CALL
Xenon Pharmaceuticals
XENE
$6.06B
| $2.69M | 0.09% |
+150,100
| New | +$2.54M |
|
182
Eledon Pharmaceuticals
ELDN
$261M
| $2.68M | 0.09% |
+250,000
| New | +$3.77M |
|
183
Nuvation Bio
NUVB
$2.2B
| $2.61M | 0.09% |
250,000
+48,192
| +24% | +$539K |
|
184
Altimmune
ALT
$552M
| $2.57M | 0.09% |
181,941
+106,496
| +141% | +$1.72M |
|
185
Liquidia Corp
LQDA
$7.48B
| $2.56M | 0.09% |
951,400
| – | – |
|
186
Passage Bio
PASG
$14.4M
| $2.55M | 0.09% |
7,293
+458
| +7% | +$196K |
|
|
ITCI
187
PUT
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $2.54M | 0.09% |
75,000
-25,000
| -25% | -$867K |
|
|
ATXS
188
DELISTED
Astria Therapeutics
ATXS
| $2.46M | 0.08% |
142,166
+33,833
| +31% | +$611K |
|
|
ZGNX
189
DELISTED
Zogenix, Inc.
ZGNX
| $2.42M | 0.08% |
124,091
-50,000
| -29% | -$1.03M |
|
|
FNCH
190
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
| $2.39M | 0.08% |
+5,000
| New | +$2.55M |
|
|
MRUS
191
DELISTED
Merus
MRUS
| $2.32M | 0.08% |
111,223
-425,698
| -79% | -$9.83M |
|
|
ICPT
192
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $2.31M | 0.08% |
+100,000
| New | +$2.79M |
|
193
Zai Lab
ZLAB
$2.06B
| $2.25M | 0.08% |
+17,000
| New | +$2.63M |
|
194
Orchestra BioMed
OBIO
$238M
| $2.25M | 0.08% |
+200,000
| New | +$2.44M |
|
|
TRIL
195
CALL
DELISTED
Trillium Therapeutics Inc.
TRIL
| $2.15M | 0.07% |
200,000
| – | – |
|
|
BGMS
196
Bio Green Med Solution Inc
BGMS
$4.91M
| $2.13M | 0.07% |
83
-26
| -24% | -$732K |
|
197
CALL
EyePoint Inc
EYPT
$1.03B
| $2.12M | 0.07% |
208,500
+190,600
| +1,065% | +$2.15M |
|
|
AGTC
198
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $2.11M | 0.07% |
415,884
-130,000
| -24% | -$674K |
|
199
PUT
Ultragenyx Pharmaceutical
RARE
$2.45B
| $2.09M | 0.07% |
+18,400
| New | +$2.5M |
|
|
RGLS
200
DELISTED
Regulus Therapeutics
RGLS
| $1.94M | 0.07% |
+124,599
| New | +$1.84M |
|
Similar funds
FLII
NHAS
HCA
GX
WCM
MP
IA
IB
Ikarian Capital's Q1 2021 Portfolio in Review
As of Q1 2021, Ikarian Capital held 350 positions worth $2.97B, up 31% from $2.27B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Ikarian Capital deployed $803M of net new capital in Q1 2021, opening 119 new positions and adding to 64 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 24% a quarter earlier, followed by Consumer Staples and Financials.
On the sell side, the largest reduction was Morphic Holding, Inc. Common Stock, an estimated $21.4M trimmed.
- Ikarian Capital's largest Q1 2021 buy was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.
- Ikarian Capital added most to X4 Pharmaceuticals in Q1 2021, an estimated $15.7M increase.
- Ikarian Capital's biggest Q1 2021 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $21.4M.
- Ikarian Capital fully exited Bristol-Myers Squibb in Q1 2021, selling an estimated $17.9M.
- Ikarian Capital's ten largest holdings make up 34% of its $2.97B portfolio in Q1 2021.
- Ikarian Capital opened 119 new positions and closed 59 in Q1 2021.
- Ikarian Capital's portfolio value rose 31% quarter-over-quarter to $2.97B.
Based on Ikarian Capital's 13F filing for Q1 2021, filed 17 May 2021.